Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials

被引：12
作者：
Allan, John N.
Shanafelt, Tait
Wiestner, Adrian
Moreno, Carol
O'Brien, Susan M.
Braggio, Esteban
Liu, Emily
Dean, James P.
Lai, Dominic
Ahn, Inhye E.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134431
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
[41]   Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation [J].
Huber, Henriette ;
Tausch, Eugen ;
Schneider, Christof ;
Edenhofer, Simone ;
Von Tresckow, Julia ;
Robrecht, Sandra ;
Giza, Adam ;
Zhang, Can ;
Furstenau, Moritz ;
Dreger, Peter ;
Ritgen, Matthias ;
Illmer, Thomas ;
Illert, Anna Lena ;
Duerig, Jan ;
Boettcher, Sebastian ;
Niemann, Carsten Utoft ;
Kneba, Michael ;
Fink, Anna-Maria ;
Fischer, Kirsten ;
Doehner, Hartmut ;
Hallek, Michael ;
Eichhorst, Barbara ;
Stilgenbauer, Stephan .
BLOOD, 2022, 140
[42]   Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study [J].
Mauro, Francesca Romana ;
Tedeschi, Alessandra ;
Piciocchi, Alfonso ;
Motta, Marina ;
Iannella, Emilia ;
Farina, Lucia ;
Scarfo, Lydia ;
Marasca, Roberto ;
Coscia, Marta ;
Cortelezzi, Agostino ;
Laurenti, Luca ;
Melpignano, Angela ;
Zinzani, Pier Luigi ;
Molica, Stefano ;
Re, Francesca ;
Andriani, Alessandro ;
Vincelli, Donatella Iolanda ;
Visco, Carlo ;
Gozzetti, Alessandro ;
Orlandi, Ester Maria ;
Trentin, Livio ;
Tani, Monica ;
Califano, Catello ;
Tagariello, Giuseppe ;
Ghia, Paolo ;
Caputo, Maria Denise ;
Salaroli, Adriano ;
Innocenti, Idanna ;
Frustaci, Anna ;
Vitale, Candida ;
Petulla, Marta ;
de Fabritiis, Paolo ;
Vignetti, Marco ;
Fazi, Paola ;
Foa, Robin .
BLOOD, 2016, 128 (22)
[43]   Long-Term Efficacy and Safety of Single-Agent Ibrutinib at 3 Years Follow-up in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL) [J].
O'Brien, Susan M. ;
Jones, Jeffrey A. ;
Furman, Richard R. ;
Coutre, Steven E. ;
Flinn, Ian W. ;
Burger, Jan A. ;
Blum, Kristie A. ;
Sharman, Jeff P. ;
Wierda, William G. ;
Zhao, Weiqiang ;
Heerema, Nyla A. ;
Johnson, Amy J. ;
Tran, Anh ;
Zhou, Cathy ;
Bilotti, Elizabeth ;
James, Danelle F. ;
Byrd, John C. .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 :S206-S206
[44]   Final Analysis of the Prospective Multicenter CLL2- GIVe Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation [J].
Huber, H. ;
Edenhofer, S. ;
von, Tresckow J. .
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) :9-10
[45]   A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction [J].
Cencini, Emanuele ;
Sozzi, Elisa ;
Sicuranza, Anna ;
Fabbri, Alberto ;
Raspadori, Donatella ;
Lauria, Francesco ;
Forconi, Francesco .
BRITISH JOURNAL OF HAEMATOLOGY, 2011, 154 (02) :271-274
[46]   LONG-TERM FOLLOW-UP OF SINGLE-AGENT IBRUTINIB IN FIRST-LINE AND RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA [J].
Reid, Mark ;
Settlemire, Jillian ;
Liu, Emily ;
Amaya-Chanaga, Carlos ;
Coutre, Steven ;
Byrd, John .
ONCOLOGY NURSING FORUM, 2019, 46 (02)
[47]   17P (TP53) Deletion Determines Worse Survival in Diffuse Large B-Cell Lymphoma Patients After First-Line Treatment With Immunochemotherapy: A Retrospective Study of 151 Patients [J].
Alonso, David ;
Navarro, Almudena ;
Alejo, Elena ;
Garcia, Maria ;
Antonio Queizan, Jose ;
Cabero, Almudena ;
Eugenia Alonso, Maria ;
Garcia-Bacelar, Ana ;
Davila, Julio ;
Labrador, Jorge ;
Fernandez, Silvia ;
Albarran, Beatriz ;
Aguilar, Carlos ;
Pardal, Emilia ;
De Cabo, Erick ;
Jesus Penarrubia, Maria ;
Cidoncha, Borja ;
Martinez, Gerardo ;
Villaescusa, Teresa ;
Maria Navarro, Jose ;
Patricia Gomez, Sandra ;
Puerta, Carlos ;
Garcia-Jaen, Pablo ;
Gabriela Zapata, Evelyn ;
Clavo, Diego ;
Jose Malaver, Rafael ;
Teresa Fuentes, Cristina ;
Fernandez, Adolfo ;
Santos, Carmen ;
Martin, Alejandro ;
Alcoceba, Miguel ;
Norma Gutierrez, Carmen .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 :S435-S436
[48]   Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton's Tyrosine Kinase Inhibitor-Based Therapy [J].
Cherng, Hua-Jay J. ;
Khwaja, Raamis ;
Kanagal-Shamanna, Rashmi ;
Burger, Jan A. ;
Thompson, Philip A. ;
Ferrajoli, Alessandra ;
Estrov, Zeev E. ;
Sasaki, Koji ;
Sampath, Deepa ;
Tang, Guilin ;
Wang, Xuemei ;
Kantarjian, Hagop ;
Keating, Michael J. ;
Wierda, William G. ;
Jain, Nitin .
BLOOD, 2021, 138
[49]   Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study [J].
Jan A. Burger ;
Paul M. Barr ;
Tadeusz Robak ;
Carolyn Owen ;
Paolo Ghia ;
Alessandra Tedeschi ;
Osnat Bairey ;
Peter Hillmen ;
Steven E. Coutre ;
Stephen Devereux ;
Sebastian Grosicki ;
Helen McCarthy ;
David Simpson ;
Fritz Offner ;
Carol Moreno ;
Sandra Dai ;
Indu Lal ;
James P. Dean ;
Thomas J. Kipps .
Leukemia, 2020, 34 :787-798
[50]   Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study [J].
Burger, Jan A. ;
Barr, Paul M. ;
Robak, Tadeusz ;
Owen, Carolyn ;
Ghia, Paolo ;
Tedeschi, Alessandra ;
Bairey, Osnat ;
Hillmen, Peter ;
Coutre, Steven E. ;
Devereux, Stephen ;
Grosicki, Sebastian ;
McCarthy, Helen ;
Simpson, David ;
Offner, Fritz ;
Moreno, Carol ;
Dai, Sandra ;
Lal, Indu ;
Dean, James P. ;
Kipps, Thomas J. .
LEUKEMIA, 2020, 34 (03) :787-798
12345